|
|
Article: EKR Therapeutics Receives Notice of Patent Allowance for Ready-to-Use Cardene[R] I.V. Bags, a Specialty Product Line for Treating Acute Hypertension in Emergency and Critical-Care Settings.
- Article from:
- Biotech Week
- Article date:
- November 11, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
EKR Therapeutics, Inc., a specialty pharmaceutical company focused on commercializing acute-care hospital products, announced that it received notice of patent allowance from the U.S. Patent and Trademark Office for its Ready-to-Use (RTU) Cardene[R] I.V. (nicardipine hydrochloride) Premixed Injection (see also EKR Therapeutics, Inc.).
Once issued, the patent will cover pharmaceutical formulations of RTU Cardene I.V. through 2027. Additionally, upon issuance of the patent, EKR will file the patent with the U.S. Food and Drug Administration (FDA) for publication in the agency's Orange Book which will provide additional protection relative to EKR's intellectual ...